{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:48:53Z","timestamp":1791121733767,"version":"4.1.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,1,6]],"date-time":"2019-01-06T00:00:00Z","timestamp":1546732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000090","name":"Department of Defense Congressionally Directed Medical Research Program","doi-asserted-by":"crossref","award":["W81XWH-15-1-0446"],"award-info":[{"award-number":["W81XWH-15-1-0446"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000090","name":"Department of Defense Congressionally Directed Medical Research Program","doi-asserted-by":"crossref","award":["W81XWH-16-1-0104"],"award-info":[{"award-number":["W81XWH-16-1-0104"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000055","name":"National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["R0-DC005575"],"award-info":[{"award-number":["R0-DC005575"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000055","name":"National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["R01-DC012115"],"award-info":[{"award-number":["R01-DC012115"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,18]]},"DOI":"10.1093\/neuonc\/noz002","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T15:11:18Z","timestamp":1546614678000},"page":"486-497","source":"Crossref","is-referenced-by-count":39,"title":["Preclinical assessment of MEK1\/2 inhibitors for neurofibromatosis type 2\u2013associated schwannomas reveals differences in efficacy and drug resistance development"],"prefix":"10.1093","volume":"21","author":[{"given":"Marisa A","family":"Fuse","sequence":"first","affiliation":[{"name":"Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida (UCF), Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine T","family":"Dinh","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Vitte","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA and Jonsson Comprehensive Cancer Center, University of California at Los Angeles (UCLA), Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kirkpatrick","sequence":"additional","affiliation":[{"name":"Leibniz Institute on Aging, Fritz Lipmann Institute, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mindos","sequence":"additional","affiliation":[{"name":"Leibniz Institute on Aging, Fritz Lipmann Institute, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephani Klingeman","family":"Plati","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida (UCF), Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan I","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[{"name":"Center for Childhood Cancer and Blood Diseases, Nationwide Children\u2019s Hospital"},{"name":"Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Carlstedt","sequence":"additional","affiliation":[{"name":"Leibniz Institute on Aging, Fritz Lipmann Institute, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Clara","family":"Franco","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida (UCF), Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Brnjos","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida (UCF), Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson","family":"Nagamoto","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida (UCF), Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra M","family":"Petrilli","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida (UCF), Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja J","family":"Copik","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida (UCF), Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia N","family":"Soulakova","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida (UCF), Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Bracho","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Mittal","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rulong","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred F","family":"Telischi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Morrison","sequence":"additional","affiliation":[{"name":"Leibniz Institute on Aging, Fritz Lipmann Institute, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Giovannini","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA and Jonsson Comprehensive Cancer Center, University of California at Los Angeles (UCLA), Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Zhong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA"},{"name":"Department of Human Genetics, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Sheng","family":"Chang","sequence":"additional","affiliation":[{"name":"Center for Childhood Cancer and Blood Diseases, Nationwide Children\u2019s Hospital"},{"name":"Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Fernandez-Valle","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida (UCF), Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,1,6]]},"reference":[{"issue":"6429","key":"key\n\t\t\t\t2019031815564995800_CIT0001","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/363515a0","article-title":"Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2","volume":"363","author":"Rouleau","year":"1993","journal-title":"Nature"},{"issue":"5","key":"key\n\t\t\t\t2019031815564995800_CIT0002","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","article-title":"A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor","volume":"72","author":"Trofatter","year":"1993","journal-title":"Cell"},{"key":"key\n\t\t\t\t2019031815564995800_CIT0003","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-4-16","article-title":"Neurofibromatosis type 2 (NF2): a clinical and molecular review","volume":"4","author":"Evans","year":"2009","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"key\n\t\t\t\t2019031815564995800_CIT0004","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ajmg.a.34359","article-title":"Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2","volume":"158A","author":"Blakeley","year":"2012","journal-title":"Am J Med Genet A"},{"key":"key\n\t\t\t\t2019031815564995800_CIT0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.wneu.2017.08.159","article-title":"A systematic review of radiosurgery versus surgery for neurofibromatosis type 2 vestibular schwannomas","volume":"109","author":"Chung","year":"2018","journal-title":"World Neurosurg"},{"issue":"4","key":"key\n\t\t\t\t2019031815564995800_CIT0006","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/jmg.2005.036319","article-title":"Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes","volume":"43","author":"Evans","year":"2006","journal-title":"J Med Genet"},{"issue":"4","key":"key\n\t\t\t\t2019031815564995800_CIT0007","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10143-016-0728-5","article-title":"Clinical outcome of neurofibromatosis type 2-related vestibular schwannoma: treatment strategies and challenges","volume":"39","author":"Kim","year":"2016","journal-title":"Neurosurg Rev"},{"issue":"5","key":"key\n\t\t\t\t2019031815564995800_CIT0008","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.pjnns.2015.06.008","article-title":"Strategy for the surgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2","volume":"49","author":"Nowak","year":"2015","journal-title":"Neurol Neurochir Pol"},{"key":"key\n\t\t\t\t2019031815564995800_CIT0009","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3171\/2014.7.GKS141311","article-title":"Malignant transformation in vestibular schwannoma: report of a single case, literature search, and debate","volume":"121","author":"Seferis","year":"2014","journal-title":"J Neurosurg"},{"key":"key\n\t\t\t\t2019031815564995800_CIT0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3171\/2014.8.GKS141503","article-title":"Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis type 2","volume":"121","author":"Sun","year":"2014","journal-title":"J Neurosurg"},{"issue":"6","key":"key\n\t\t\t\t2019031815564995800_CIT0011","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2559.2009.03440.x","article-title":"Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ","volume":"55","author":"Hilton","year":"2009","journal-title":"Histopathology"},{"issue":"2","key":"key\n\t\t\t\t2019031815564995800_CIT0012","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/0008-5472.CAN-06-1608","article-title":"Merlin\/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac","volume":"67","author":"Morrison","year":"2007","journal-title":"Cancer Res"},{"issue":"5","key":"key\n\t\t\t\t2019031815564995800_CIT0013","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"key":"key\n\t\t\t\t2019031815564995800_CIT0014","first-page":"1","article-title":"Allosteric MEK1\/2 inhibitors for the treatment of cancer: an overview","volume":"1","author":"McDermott","year":"2015","journal-title":"J Drug Res Dev."},{"issue":"26","key":"key\n\t\t\t\t2019031815564995800_CIT0015","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1\u2013related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"key\n\t\t\t\t2019031815564995800_CIT0016","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/glia.22391","article-title":"The role of insulin-like growth factors signaling in merlin-deficient human schwannomas","volume":"60","author":"Ammoun","year":"2012","journal-title":"Glia"},{"issue":"7","key":"key\n\t\t\t\t2019031815564995800_CIT0017","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/neuonc\/nor056","article-title":"Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2","volume":"13","author":"Ammoun","year":"2011","journal-title":"Neuro Oncol"},{"issue":"1","key":"key\n\t\t\t\t2019031815564995800_CIT0018","first-page":"23","article-title":"Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1\/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo","volume":"39","author":"Yamaguchi","year":"2011","journal-title":"Int J Oncol"},{"issue":"24","key":"key\n\t\t\t\t2019031815564995800_CIT0019","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1016\/j.bmcl.2008.10.054","article-title":"The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901","volume":"18","author":"Barrett","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"key\n\t\t\t\t2019031815564995800_CIT0020","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI60578","article-title":"MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors","volume":"123","author":"Jessen","year":"2013","journal-title":"J Clin Invest"},{"issue":"10","key":"key\n\t\t\t\t2019031815564995800_CIT0021","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/pbc.25546","article-title":"Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1","volume":"62","author":"Jousma","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"key\n\t\t\t\t2019031815564995800_CIT0022","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1060028016672037","article-title":"Cobimetinib","volume":"51","author":"Signorelli","year":"2017","journal-title":"Ann Pharmacother"},{"issue":"11","key":"key\n\t\t\t\t2019031815564995800_CIT0023","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1158\/1078-0432.CCR-12-0445","article-title":"Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor","volume":"18","author":"Wong","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"key\n\t\t\t\t2019031815564995800_CIT0024","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00280-012-1988-6","article-title":"PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts","volume":"71","author":"Choo","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"key\n\t\t\t\t2019031815564995800_CIT0025","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/0008-5472.CAN-11-1515","article-title":"Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition","volume":"72","author":"Hoeflich","year":"2012","journal-title":"Cancer Res"},{"issue":"5","key":"key\n\t\t\t\t2019031815564995800_CIT0026","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1021\/ml300049d","article-title":"Novel carboxamide-based allosteric MEK inhibitors: discovery and optimization efforts toward XL518 (GDC-0973)","volume":"3","author":"Rice","year":"2012","journal-title":"ACS Med Chem Lett"},{"issue":"5","key":"key\n\t\t\t\t2019031815564995800_CIT0027","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s10637-016-0374-3","article-title":"A first-in-human phase I study to evaluate the MEK1\/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors","volume":"34","author":"Rosen","year":"2016","journal-title":"Invest New Drugs"},{"issue":"5","key":"key\n\t\t\t\t2019031815564995800_CIT0028","first-page":"471","article-title":"A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2","volume":"6","author":"Petrilli","year":"2014","journal-title":"Am J Transl Res"},{"issue":"11","key":"key\n\t\t\t\t2019031815564995800_CIT0029","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1158\/1535-7163.MCT-17-0417","article-title":"Combination therapy with c-Met and Src inhibitors induces caspase-dependent apoptosis of merlin-deficient schwann cells and suppresses growth of schwannoma cells","volume":"16","author":"Fuse","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"key\n\t\t\t\t2019031815564995800_CIT0030","doi-asserted-by":"crossref","first-page":"31666","DOI":"10.18632\/oncotarget.15912","article-title":"Ponatinib promotes a G1 cell-cycle arrest of merlin\/NF2-deficient human schwann cells","volume":"8","author":"Petrilli","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"key\n\t\t\t\t2019031815564995800_CIT0031","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1101\/gad.13.8.978","article-title":"Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein","volume":"13","author":"Giovannini","year":"1999","journal-title":"Genes Dev"},{"issue":"4","key":"key\n\t\t\t\t2019031815564995800_CIT0032","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/neuonc\/not242","article-title":"mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma","volume":"16","author":"Giovannini","year":"2014","journal-title":"Neuro Oncol"},{"issue":"4","key":"key\n\t\t\t\t2019031815564995800_CIT0033","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1021\/pr101065j","article-title":"Andromeda: a peptide search engine integrated into the MaxQuant environment","volume":"10","author":"Cox","year":"2011","journal-title":"J Proteome Res"},{"issue":"9","key":"key\n\t\t\t\t2019031815564995800_CIT0034","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1093\/bioinformatics\/bti270","article-title":"Use of within-array replicate spots for assessing differential expression in microarray experiments","volume":"21","author":"Smyth","year":"2005","journal-title":"Bioinformatics"},{"issue":"5","key":"key\n\t\t\t\t2019031815564995800_CIT0035","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","article-title":"GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition","volume":"17","author":"Gilmartin","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"5","key":"key\n\t\t\t\t2019031815564995800_CIT0036","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/neuonc\/nov200","article-title":"Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis","volume":"18","author":"Blakeley","year":"2016","journal-title":"Neuro Oncol"},{"issue":"2","key":"key\n\t\t\t\t2019031815564995800_CIT0037","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","article-title":"Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas","volume":"122","author":"Goutagny","year":"2015","journal-title":"J Neurooncol"},{"issue":"9","key":"key\n\t\t\t\t2019031815564995800_CIT0038","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","article-title":"Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis","year":"2012","journal-title":"Neuro Oncol"},{"issue":"2","key":"key\n\t\t\t\t2019031815564995800_CIT0039","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/neuonc\/not150","article-title":"Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol"},{"issue":"7","key":"key\n\t\t\t\t2019031815564995800_CIT0040","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","article-title":"Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients","volume":"31","author":"Plotkin","year":"2010","journal-title":"Otol Neurotol"},{"issue":"6","key":"key\n\t\t\t\t2019031815564995800_CIT0041","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","article-title":"Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients","volume":"33","author":"Plotkin","year":"2012","journal-title":"Otol Neurotol"},{"issue":"4","key":"key\n\t\t\t\t2019031815564995800_CIT0042","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ccr.2011.02.017","article-title":"A tight junction-associated merlin-angiomotin complex mediates merlin\u2019s regulation of mitogenic signaling and tumor suppressive functions","volume":"19","author":"Yi","year":"2011","journal-title":"Cancer Cell"},{"issue":"6","key":"key\n\t\t\t\t2019031815564995800_CIT0043","doi-asserted-by":"crossref","first-page":"e1300622","DOI":"10.1080\/23723556.2017.1300622","article-title":"Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1\/2 inhibition in triple-negative breast cancer","volume":"4","author":"Bevill","year":"2017","journal-title":"Mol Cell Oncol"},{"issue":"3","key":"key\n\t\t\t\t2019031815564995800_CIT0044","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/2159-8290.CD-16-0653","article-title":"Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex","volume":"7","author":"Zawistowski","year":"2017","journal-title":"Cancer Discov"},{"issue":"5","key":"key\n\t\t\t\t2019031815564995800_CIT0045","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.celrep.2016.06.091","article-title":"Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer","volume":"16","author":"Kurimchak","year":"2016","journal-title":"Cell Rep"},{"issue":"3","key":"key\n\t\t\t\t2019031815564995800_CIT0046","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.celrep.2015.03.037","article-title":"Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains","volume":"11","author":"Stuhlmiller","year":"2015","journal-title":"Cell Rep"},{"issue":"5","key":"key\n\t\t\t\t2019031815564995800_CIT0047","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1091\/mbc.e05-10-0929","article-title":"Arl2 and Arl3 regulate different microtubule-dependent processes","volume":"17","author":"Zhou","year":"2006","journal-title":"Mol Biol Cell"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/21\/4\/486\/28085780\/noz002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T10:50:58Z","timestamp":1573642258000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/21\/4\/486\/5274482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,6]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,1,6]]},"published-print":{"date-parts":[[2019,3,18]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noz002","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2019,1,6]]}}}